ArticleAlzheimer's research & therapy2024
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
Article in Alzheimer's research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Blood-based multiplex nanobiosensing of Alzheimer's disease biomarkers: from nanoengineered ınterfaces to clinical translation.Metabolic brain disease · 2026Review
- Long term clinical performance and analytical robustness of the Lumipulse plasma p-tau217 assay in routine clinical practice.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma p-tau217 measured by the Elecsys automated immunoassay: Prospective validation in a heterogeneous memory clinic cohort.Journal of Alzheimer's disease : JAD · 2026Article
- The complement system in Alzheimer's disease: evaluating biomarker potential in a complex neuroimmune context.Journal of neuroinflammation · 2026Review
- The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.Neurology · 2026Observational
- Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Stable episodic memory and high education do not influence the rate of Alzheimer's disease pathology as measured by plasma p-tau217.bioRxiv : the preprint server for biology · 2026Article
- Analytical and clinical validation of the Lumipulse G plasma p-tau217 assay for clinical implementation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma brain-derived p-tau217 for the identification of amyloid status in a memory clinic cohort.Journal of neurology · 2026Article
- Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer's disease in community cohorts.Alzheimer's research & therapy · 2026Article
- Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?Clinical chemistry · 2026Article
- The Alzheimer's Disease Diagnosis and Plasma Phospho-Tau217 (ADAPT) study stage 1: Validating clinical cut-points against CSF and amyloid PET.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Translating blood-based biomarkers into Alzheimer's disease clinical practice: screening, diagnosis, and longitudinal monitoring.Frontiers in aging neuroscience · 2026Review
- Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain-Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease.Journal of neurochemistry · 2025Article
- Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization Consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Standardized Procedures for Blood and Cerebrospinal Fluid Collection and Storage in Neurodegenerative Biomarker Research: A Comprehensive Review.Dementia and neurocognitive disorders · 2025Review
- Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort.Acta neuropathologica communications · 2025Article
- Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionPre-analytical factors can cause substantial variability in the measurements of cerebrospinal fluid (CSF) and plasma biomarkers of Alzheimer's disease (AD). However, their effects on the performance of one of the most promising plasma AD biomarkers, phosphorylated tau (p-tau)217, are not known.
methodsWe included 50 amyloid-β positive (Aβ
resultsIn the whole cohort (combining Aβ
conclusionCentrifugation improved the performance of plasma p-tau217, but thawing temperatures and up to three freeze-thaw cycles did not have a significant impact. These results may inform the future development of standardized sample-handling protocols for AD biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.